Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

• Status: Withdrawn
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the safety and efficacy of Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with glaucoma or ocular hypertension who have elevated IOP on dorzolamide hydrochloride/timolol maleate combination therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Brimonidine Tartrate; Dorzolamide; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol

Criteria

Inclusion Criteria:

• Diagnosis of ocular hypertension or glaucoma in each eye

• Requires IOP-lowering treatment in both eyes

Exclusion Criteria:

• Use of dorzolamide or carbonic anhydrase within 4 weeks

• Any other active ocular disease other than ocular hypertension or glaucoma (eg, uveitis, ocular infections or severe dry eye)

• Required chronic use of ocular medications other than study medication during the study (intermittent use of certain products eg, artificial tears are permitted)

• Use of oral, injectable or topical ophthalmic steroids within 21 days

• Any eye laser surgery within 3 months

• Any intraocular surgery (eg cataract surgery) within 6 months